The G-EPOSS study is a prospective, non-interventional, German multicenter study assessing the real-world effectiveness and safety of guselkumab, a monoclonal antibody targeting interleukin-23, in patients with moderate-to-severe plaque psoriasis. The study aimed to evaluate its impact on skin symptoms, health-related quality of life (HRQoL), sexuality, and perceived stigmatization. The primary endpoint was the proportion of patients achieving a Psoriasis Area and Severity Index (PASI) score ≤ 3 at Week 28. Secondary endpoints included Nail Psoriasis Severity Index (NAPSI), anogenital Physician’s Global Assessment (aPGA), and Dermatology Life Quality Index (DLQI), along with assessments of sexuality and stigmatization using specific patient questionnaires.

The study included 293 patients, with a mean age of 45.6 years and a disease duration of 17.6 years. At Week 28, 83% of patients achieved PASI ≤ 3, with 56.2% reaching PASI ≤ 1 and 35.1% achieving PASI = 0. Significant improvements were observed in NAPSI, aPGA, and DLQI scores. Moreover, patients reported enhanced HRQoL, improved sex life, and decreased perceived stigmatization, with a marked reduction in sexual difficulties from 53.6% at baseline to 12.1% at Week 28. No new safety signals were observed, demonstrating guselkumab’s positive impact on both skin symptoms and quality of life for patients with psoriasis.

Reference: Gerdes S, Ostendorf R, Süß A, et al. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study. J Eur Acad Dermatol Venereol. 2025 Mar;39 Suppl 1(Suppl 1):15-26. doi: 10.1111/jdv.19927. Epub 2024 Apr 11. PMID: 38602225; PMCID: PMC11862875.